Corcept Therapeutics (CORT) Short term Debt (2012 - 2023)

Corcept Therapeutics (CORT) posted Short term Debt of $14.0 million for Q4 2023, little changed sequentially from $14.0 million in Q3 2023, and little changed YoY from $14.0 million in Q4 2022.

Corcept Therapeutics (CORT) Short term Debt (2012 - 2023) Analysis & Trends

Corcept Therapeutics has reported Short term Debt for 8 years, with the latest figure at $14.0 million in Q4 2023.

  • Quarterly Short term Debt changed 0.0% year-over-year to $14.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $14.0 million (changed 0.0% YoY) and the FY2023 annual result came in at $14.0 million, changed 0.0% from the prior year.
  • Short term Debt steadied at $14.0 million in Q4 2023 per CORT's latest filing, from $14.0 million in the prior quarter.
  • Over five years, Short term Debt peaked at $14.0 million in Q4 2022 and troughed at $14.0 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Corcept Therapeutics 12.37 Bn 12.07 Bn 252.09 Mn

Historic Data

Download Data
DateValue
Dec 31, 2023 14.00 Mn
Sep 30, 2023 14.00 Mn
Jun 30, 2023 14.00 Mn
Mar 31, 2023 14.00 Mn
Dec 31, 2022 14.00 Mn
Jun 30, 2017 4.57 Mn
Mar 31, 2017 10.11 Mn
Dec 31, 2016 14.66 Mn
Sep 30, 2016 18.73 Mn
Jun 30, 2016 18.56 Mn
Mar 31, 2016 16.32 Mn
Dec 31, 2015 14.97 Mn
Sep 30, 2015 13.51 Mn
Jun 30, 2015 12.03 Mn
Mar 31, 2015 10.66 Mn
Dec 31, 2014 9.42 Mn
Sep 30, 2014 8.66 Mn
Jun 30, 2014 7.40 Mn
Mar 31, 2014 6.90 Mn
Dec 31, 2013 5.74 Mn